Back to first-pass browser

First-pass extracted concept

combined optogenetic clinical study with gene therapy medicinal product and light-stimulation medical device

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The abstract describes optogenetic clinical studies as simultaneously testing a viral gene-transfer product and a light-stimulation device. This combined setup is central to the paper's regulatory analysis.

Source 1DOIPubMed

Resources required

A viral vector for gene transfer and a medical device for light stimulation are explicitly described. Both components are part of the clinical study configuration discussed.

Source 1DOIPubMed

What problem it solves

It provides the practical treatment architecture through which optogenetic therapy can be delivered in patients with retinitis pigmentosa. The paper uses this setup to analyze regulatory consequences.

Source 1DOIPubMed

What it does not solve

The abstract says this setup does not resolve the lack of specific EU regulation for combined studies. Instead, it creates unresolved legal issues.

Source 1DOIPubMed

Alternatives

The abstract does not name alternative clinical architectures. It only distinguishes the medicinal product component from the medical device component.

Source 1DOIPubMed

Evidence Snippets

This raises unresolved legal issues and is the case for optogenetic clinical studies, when for the gene transfer a viral vector classified as gene therapy medicinal product (GTMP) and for the light stimulation a device qualified as medical device are tested simultaneously.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1regulatory gapsupports2025Source 1DOIPubMed

Equivalent rare-disease orphan regulation does not exist for medical devices used in optogenetic therapies.

Quoted textsource-backed
However, equivalent regulation does not exist for medical devices for rare diseases.
Claim 2regulatory issuesupports2025Source 1DOIPubMed

Optogenetic clinical studies that simultaneously test a viral vector gene therapy medicinal product and a light-stimulation medical device raise unresolved legal issues in the EU.

Quoted textsource-backed
This raises unresolved legal issues and is the case for optogenetic clinical studies, when for the gene transfer a viral vector classified as gene therapy medicinal product (GTMP) and for the light stimulation a device qualified as medical device are tested simultaneously.
Claim 3regulatory requirementsupports2025Source 1DOIPubMed

For EU combined studies evaluating both a medicinal product and a medical device, the requirements for clinical trials with medicinal products and for clinical investigations on medical devices both apply.

Quoted textsource-backed
Because at EU level, so far, no specific regulation exists for clinical studies in which a medicinal product and a medical device are evaluated simultaneously (combined studies) the requirements for clinical trials with medicinal products as well as those for clinical investigations on medical devices apply.